The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 17, 2023

Filed:

Mar. 02, 2023
Applicant:

Shanghai Institute for Advanced Study Zhe Jiang University, Shanghai, CN;

Inventors:

Ruhong Zhou, Stormville, NY (US);

Lianxue Zhang, Hangzhou, CN;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/502 (2006.01); A61K 31/704 (2006.01); A61K 9/51 (2006.01); A61P 35/00 (2006.01); B82Y 5/00 (2011.01); B82Y 40/00 (2011.01);
U.S. Cl.
CPC ...
A61K 31/502 (2013.01); A61K 9/5161 (2013.01); A61K 9/5192 (2013.01); A61K 31/704 (2013.01); A61P 35/00 (2018.01); B82Y 5/00 (2013.01); B82Y 40/00 (2013.01);
Abstract

A high-efficiency anti-tumor nano-drug delivery system containing hydralazine (hydralazine-nanoparticles abbreviated as H-NPs) is provided. The drug delivery system takes hydralazine and doxorubicin combined by a π-π bond as a hydrophobic core and takes dextran as a hydrophilic shell. The high-effective anti-tumor nano-drug delivery system containing hydralazine can increase the vascular permeability and blood perfusion of the tumor site, improve the enrichment and penetration of nanoparticles in the tumor, reduce tumor hypoxia, increase the sensitivity of the tumor to a chemotherapy drug doxorubicin, and significantly improve its anti-tumor effect by expanding the tumor blood vessels and regulating tumor microenvironment (TME).


Find Patent Forward Citations

Loading…